BAY-3547922
- Generic Name
- BAY-3547922
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer
- First Posted Date
- 2025-01-08
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 148
- Registration Number
- NCT06764316
- Locations
- 🇫🇮
Tampere University Hospital, Tampere, Finland
🇫🇮Turku University Hospital, Turku, Finland
🇨🇦University of Alberta - Cross Cancer Institute (CCI), Edmonton, Alberta, Canada
A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers
Phase 1
Completed
- Conditions
- Solid TumorsHepatocellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT06345001
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸City of Hope - Duarte Cancer Center, Duarte, California, United States
🇺🇸University of Southern California (USC) - Norris Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath